Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced participation in several virtual conferences, aimed at enhancing its profile in the biopharmaceutical sector. Key events include the Morgan Stanley Virtual Asia Healthcare Conference on May 13-14, 2021, the ICA China Healthcare Corporate Day on May 18, 2021, and the Sachs Associates 7th Annual Immuno-Oncology Innovation Forum on May 20, 2021. Gracell focuses on developing affordable cell therapies using its FasTCAR and TruUCAR technologies, addressing challenges in CAR-T therapies.

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

Morgan Stanley Virtual Asia Healthcare Conference
One-on-one and small group meetings: May 13-14, 2021
For more information, please contact your Morgan Stanley representative.

ICA China Healthcare Corporate Day
One-on-one and small group meetings: May 18, 2021
For more information, please contact your ICA representative.

Sachs Associates 7^th Annual Immuno-Oncology Innovation Forum
Chinese Innovation in IO Panel: 10:10am EDT, May 20, 2021
For more information, please contact your Sachs Associates representative.

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com
Follow @GracellBio on LinkedIn

Media Contact

Marvin Tang
Marvin.tang@gracellbio.com

Investor Contact
Gracie Tong
Gracie.tong@gracellbio.com

FAQ

What virtual conferences is Gracell Biotechnologies participating in May 2021?

Gracell will participate in the Morgan Stanley Virtual Asia Healthcare Conference on May 13-14, the ICA China Healthcare Corporate Day on May 18, and the Sachs Associates 7th Annual Immuno-Oncology Innovation Forum on May 20, 2021.

What is the focus of Gracell's development efforts?

Gracell Biotechnologies is dedicated to developing highly efficacious and affordable cell therapies for cancer treatment.

How does Gracell aim to overcome CAR-T therapy challenges?

Gracell utilizes its FasTCAR and TruUCAR technology platforms to address manufacturing time, production quality, cost, and effectiveness for solid tumors.

When is the Sachs Associates Immuno-Oncology Innovation Forum?

The Sachs Associates 7th Annual Immuno-Oncology Innovation Forum is scheduled for May 20, 2021, with Gracell participating in a panel at 10:10 am EDT.

What is the stock symbol for Gracell Biotechnologies?

Gracell Biotechnologies is listed under the stock symbol GRCL.